Potential role of gastrointestinal microbiota composition in prostate cancer risk

Infectious Agents and Cancer

Michael E Scheurer²  Martha P Mims¹  Yanhong Liu²  Nadim J Ajami³  Joseph F Petrosino³  E Susan Amirian² 

[1] Department of Medicine, Baylor College of Medicine, One Baylor Plaza MS:BCM305, 77030 Houston, TX, USA;Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza MS:BCM305, 77030 Houston, TX, USA;Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, One Baylor Plaza MS:BCM305, 77030 Houston, TX, USA

关键词: Metabolic process;    Prostate cancer;    Metagenome;    Human microbiome;   

Others  :  802591
DOI  :  10.1186/1750-9378-8-42

 received in 2013-06-11, accepted in 2013-10-12,  发布年份 2013

【 摘 要 】

Background

Among men in the U.S., prostate cancer is the most common cancer and the second leading cause of cancer death. Despite its prevalence, there are few established risk factors for prostate cancer. Some studies have found that intake of certain foods/nutrients may be associated with prostate cancer risk, but few have accounted for how intake and metabolic factors may interact to influence bioavailable nutrient levels and subsequent disease risk.

Presentation of the hypothesis

The composition of the gastrointestinal (GI) microbiome may influence metabolism of dietary compounds and nutrients (e.g., plant phenols, calcium, choline) that may be relevant to prostate cancer risk. We, therefore, propose the hypothesis that GI microbiota may have a markedly different composition among individuals with higher prostate cancer risk. These individuals could have microbial profiles that are conducive to intestinal inflammation and/or are less favorable for the metabolism and uptake of chemopreventive agents.

Testing the hypothesis

Because very little preliminary data exist on this potential association, a case–control study may provide valuable information on this topic. Such a study could evaluate whether the GI microbial profile is markedly different between three groups of individuals: healthy men, those with latent prostate cancer, and those with invasive prostate cancer. Any findings could then be validated in a larger study, designed to collect a series of specimens over time.

Implications of the hypothesis

Given the plethora of information emerging from the Human Microbiome Project, this is an opportune time to explore associations between the microbiome and complex human diseases. Identification of profiles that alter the host’s risk for disease may clarify inconsistencies in the literature on dietary factors and cancer risk, and could provide valuable targets for novel cancer prevention strategies.

【 授权许可】

   
2013 Amirian et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]SEER stat fact sheets: prostate. [http://www.seer.cancer.gov/statfacts/html/prost.html webcite]
• [2]Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD: History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002, 99:252-259.
• [3]Wilson KM, Giovannucci EL, Mucci LA: Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 2012, 14:365-374.
• [4]Astorg P: Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes Control 2004, 15:367-386.
• [5]Page WF, Braun MM, Partin AW, Caporaso N, Walsh P: Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997, 33:240-245.
• [6]Sonn GA, Aronson W, Litwin MS: Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 2005, 8:304-310.
• [7]Punnen S, Hardin J, Cheng I, Klein EA, Witte JS: Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. PLoS One 2011, 6:e27711.
• [8]Major JM, Cross AJ, Watters JL, Hollenbeck AR, Graubard BI, Sinha R: Patterns of meat intake and risk of prostate cancer among African-Americans in a large prospective study. Cancer Causes Control 2011, 22:1691-1698.
• [9]Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM: Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila) 2011, 4:2110-2121.
• [10]Alexander DD, Mink PJ, Cushing CA, Sceurman B: A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. Nutr J 2010, 9:50. BioMed Central Full Text
• [11]Newmark HL, Heaney RP: Dairy products and prostate cancer risk. Nutr Cancer 2010, 62:297-299.
• [12]Lampe JW: Dairy products and cancer. J Am Coll Nutr 2011, 30:464S-470S.
• [13]Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Zeisel SH, Willett WC, Chan JM: Choline intake and risk of lethal prostate cancer: incidence and survival. Am J Clin Nutr 2012, 96:855-863.
• [14]Xie B, He H: No association between egg intake and prostate cancer risk: a meta-analysis. Asian Pac J Cancer Prev 2012, 13:4677-4681.
• [15]Montague JA, Butler LM, Wu AH, Genkinger JM, Koh WP, Wong AS, Wang R, Yuan JM, Yu MC: Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control 2012, 23:1635-1641.
• [16]Ozten-Kandas N, Bosland MC: Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants - in vivo evidence. J Carcinog 2011, 10:27.
• [17]Chan JM, Giovannucci EL: Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 2001, 23:87-92.
• [18]Gao X, LaValley MP, Tucker KL: Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2005, 97:1768-1777.
• [19]Schwartz GG, Skinner HG: A prospective study of total and ionized serum calcium and time to fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:1768-1773.
• [20]Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL: Dairy products, calcium, and prostate cancer risk in the Physicians’ health study. Am J Clin Nutr 2001, 74:549-554.
• [21]Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, et al.: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European prospective investigation into cancer and nutrition study. Am J Clin Nutr 2007, 86:672-681.
• [22]Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff V, Willett WC, Giovannucci E: Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev 2004, 13:260-269.
• [23]Teodoro AJ, Oliveira FL, Martins NB, Maia GA, Martucci RB, Borojevic R: Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int 2012, 12:36. BioMed Central Full Text
• [24]Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, Vieira R, Collings R, Harvey LJ, Sterne JA, et al.: Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr 2012, 96:111-122.
• [25]Sala-Vila A, Calder PC: Update on the relationship of fish intake with prostate, breast, and colorectal cancers. Crit Rev Food Sci Nutr 2011, 51:855-871.
• [26]Dennis LK, Snetselaar LG, Smith BJ, Stewart RE, Robbins ME: Problems with the assessment of dietary fat in prostate cancer studies. Am J Epidemiol 2004, 160:436-444.
• [27]Wei MY, Giovannucci EL: Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening Era. J Oncol 2012, 2012:271063.
• [28]Joshi AD, Corral R, Catsburg C, Lewinger JP, Koo J, John EM, Ingles SA, Stern MC: Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case–control study. Carcinogenesis 2012, 33:2108-2118.
• [29]Travis RC, Appleby PN, Siddiq A, Allen NE, Kaaks R, Canzian F, Feller S, Tjonneland A, Fons Johnsen N, Overvad K, et al.: Genetic variation in the lactase gene, dairy product intake and risk for prostate cancer in the European prospective investigation into cancer and nutrition. Int J Cancer 2012, 132:1901-1910.
• [30]Amirian ES, Ittmann MM, Scheurer ME: Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. Prostate 2011, 71:1382-1389.
• [31]Tilg H: Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010, 44(Suppl 1):S16-S18.
• [32]Tremaroli V, Backhed F: Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
• [33]Macdonald RS, Wagner K: Influence of dietary phytochemicals and microbiota on colon cancer risk. J Agric Food Chem 2012. [Epub ahead of print] PMID: 22632581
• [34]Musso G, Gambino R, Cassader M: Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011, 62:361-380.
• [35]Musso G, Gambino R, Cassader M: Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 2010, 33:2277-2284.
• [36]Haiser HJ, Turnbaugh PJ: Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res: J Italian Pharmacol Soc 2013, 69:21-31.
• [37]Dutton RJ, Turnbaugh PJ: Taking a metagenomic view of human nutrition. Curr Opin Clin Nutr 2012, 15:448-454.
• [38]Akaza H: Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the "second human genome". Cancer Sci 2012, 103:969-975.
• [39]Saad R, Rizkallah MR, Aziz RK: Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathogens 2012, 4:16. BioMed Central Full Text
• [40]Masood MI, Qadir MI, Shirazi JH, Khan IU: Beneficial effects of lactic acid bacteria on human beings. Crit Rev Microbiol 2011, 37:91-98.
• [41]Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
• [42]Russell SL, Finlay BB: The impact of gut microbes in allergic diseases. Curr Opin Gastroenterol 2012, 28:563-569.
• [43]Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, et al.: Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
• [44]Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, et al.: Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2012. doi: 10.1038/tpj.2012.43. [Epub ahead of print] PMID: 23032991
• [45]Iebba V, Nicoletti M, Schippa S: Gut microbiota and the immune system: an intimate partnership in health and disease. Int J Immunopathol Pharmacol 2012, 25:823-833.
• [46]Sanders ME, Klaenhammer TR: Invited review: the scientific basis of lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 2001, 84:319-331.
• [47]Montes RG, Bayless TM, Saavedra JM, Perman JA: Effect of milks inoculated with lactobacillus acidophilus or a yogurt starter culture in lactose-maldigesting children. J Dairy Sci 1995, 78:1657-1664.
• [48]Sekirov I, Russell SL, Antunes LC, Finlay BB: Gut microbiota in health and disease. Physiol Rev 2010, 90:859-904.
• [49]Russell W, Duthie G: Plant secondary metabolites and gut health: the case for Phenolic acids. Proc Nutr Soc 2011, 70:389-396.
• [50]Namasivayam N: Chemoprevention in experimental animals. Ann N Y Acad Sci 2011, 1215:60-71.
• [51]Plottel CS, Blaser MJ: Microbiome and malignancy. Cell host & microbe 2011, 10:324-335.
• [52]Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, Gajer P, Ravel J, Goedert JJ: Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med 2012, 10:253. BioMed Central Full Text
• [53]Cavalieri E, Rogan E: The molecular etiology and prevention of estrogen-initiated cancers. Mol Aspects Med 2013. doi: 10.1016/j.mam.2013.08.002. [Epub ahead of print] PMID: 23994691
• [54]Kasaikina MV, Kravtsova MA, Lee BC, Seravalli J, Peterson DA, Walter J, Legge R, Benson AK, Hatfield DL, Gladyshev VN: Dietary selenium affects host selenoproteome expression by influencing the gut microbiota. FASEB J: Publ Fed Am Soc Exp Biol 2011, 25:2492-2499.
• [55]Humblot C, Combourieu B, Vaisanen ML, Furet JP, Delort AM, Rabot S: 1H Nuclear magnetic resonance spectroscopy-based studies of the metabolism of food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline by human intestinal microbiota. Appl Environ Microb 2005, 71:5116-5123.
• [56]Humblot C, Murkovic M, Rigottier-Gois L, Bensaada M, Bouclet A, Andrieux C, Anba J, Rabot S: Beta-glucuronidase in human intestinal microbiota is necessary for the colonic genotoxicity of the food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline in rats. Carcinogenesis 2007, 28:2419-2425.
• [57]Rafii F, Jackson LD, Ross I, Heinze TM, Lewis SM, Aidoo A, Lyn-Cook L, Manjanatha M: Metabolism of daidzein by fecal bacteria in rats. Comparat Med 2007, 57:282-286.
• [58]Rowland IR, Davies MJ, Evans JG: Tissue content of mercury in rats given methylmercuric chloride orally: influence of intestinal flora. Arch Environ health 1980, 35:155-160.
• [59]Li K, Bihan M, Yooseph S, Methe BA: Analyses of the microbial diversity across the human microbiome. PLoS One 2012, 7:e32118.
• [60]Goodman AL, Gordon JI: Our unindicted coconspirators: human metabolism from a microbial perspective. Cell Metab 2010, 12:111-116.
• [61]Carruba G: Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007, 102:899-911.
• [62]Commane D, Hughes R, Shortt C, Rowland I: The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mutat Res 2005, 591:276-289.
• [63]Khan AA, Shrivastava A, Khurshid M: Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim Biophys Acta 1826, 2012:331-337.
• [64]Tjalsma H, Boleij A, Marchesi JR, Dutilh BE: A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012, 10:575-582.
• [65]NIH human microbiome project sampling, sequencing, and analysis protocols. [http://www.hmpdacc.org/tools_protocols/tools_protocols.php webcite]
• [66]Dave M, Higgins PD, Middha S, Rioux KP: The human gut microbiome: current knowledge, challenges, and future directions. Transl Res: J Lab Clin Med 2012, 160:246-257.
• [67]Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, Huttenhower C, Izard J: Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol 2012, 13:R42. BioMed Central Full Text
• [68]Stearns JC, Lynch MD, Senadheera DB, Tenenbaum HC, Goldberg MB, Cvitkovitch DG, Croitoru K, Moreno-Hagelsieb G, Neufeld JD: Bacterial biogeography of the human digestive tract. Sci Rep 2011, 1:170.
• [69]Huse SM, Ye Y, Zhou Y, Fodor AA: A core human microbiome as viewed through 16S rRNA sequence clusters. PLoS One 2012, 7:e34242.
• [70]Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB: Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009, 77:2367-2375.
• [71]Ogino S, Stampfer M: Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010, 102:365-367.
• [72]Ogino S, Chan AT, Fuchs CS, Giovannucci E: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011, 60:397-411.
• [73]Plowright RK, Sokolow SH, Gorman ME, Daszak P, Foley JE: Causal inference in disease ecology: investigating ecological drivers of disease emergence. Front Ecol Environ 2008, 6:420-429.
• [74]Morgan XC, Segata N, Huttenhower C: Biodiversity and functional genomics in the human microbiome. Trends Genet 2012, 29:51-58.
• [75]Conlan S, Kong HH, Segre JA: Species-level analysis of DNA sequence data from the NIH human microbiome project. PLoS One 2012, 7:e47075.
• [76]Vindigni SM, Broussard EK, Surawicz CM: Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol 2013, 7:615-628.
• [77]Aroniadis OC, Brandt LJ: Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013, 29:79-84.
• [78]Paasche S: Fecal microbiota transplantation: an innovative approach to treating clostridium difficile disease. JAAPA: J Am Acad Physic Assistants 2013, 26:46-49.